Companies Dominating the Strand Displacement Amplification Landscape
- Lucira Health Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sherlock Biosciences
- Lucigen Corporation
- Bio-Rad Laboratories Inc
- G-Biosciences
- New England Bio-Labs
- Geno Technologies Inc
- Nippon Genetics Co, Ltd.
- Proteon Pharmaceuticals
- Hopan Fine Chemicals
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of strand displacement amplification is assessed at USD 1.61 billion.
The strand displacement amplification market size was valued at USD 1.55 billion in 2024 and is expected to reach USD 2.75 billion by 2037, expanding at around 4.5% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of infectious diseases and increasing awareness about the benefits of strand displacement amplification will boost the market growth.
North America industry is anticipated to hold largest revenue share of 35% by 2037, owing to increasing demand for DNA-based testing and the implementation of advanced technologies in the region.
The major players in the market are Sherlock Biosciences, Lucigen Corporation, Bio-Rad Laboratories Inc., G-Biosciences, New England Bio-Labs, Geno Technologies Inc., and others.
